The U.S. Food and Drug Administration recently announced the first manufacturer selected for the Technology-Enabled Meaningful Patient Outcomes (TEMPO) for Digital Health Devices Pilot. The participating manufacturer intends to offer a device for use in providing care expected to be covered by the Centers for Medicare & Medicaid Services (CMS) Innovation...
Gynecologic clear cell cancers are among the rarest and most difficult cancers to treat. They can develop in the ovaries or the lining of the uterus, called the endometrium, and they often don’t respond well once standard chemotherapy stops working. For many patients, treatment options become very limited if the cancer returns.
August is Autoinflammatory Disease Awareness Month, a time to learn about a group of rare conditions that can cause repeated episodes of inflammation throughout the body. Although these diseases are uncommon, they can have a major impact on the people who live with them.
LIFYORLI is prescribed in combination with nab-paclitaxel chemotherapy for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have already received one to three prior systemic treatment regimens, including at least one that contained bevacizumab
Triple-negative breast cancer, or TNBC, is one of the most aggressive forms of breast cancer. It’s called “triple negative” because the cancer cells lack three common receptors — estrogen, progesterone, and HER2 — that some other breast cancers have.
The Centers for Disease Control and Prevention (CDC) is investigating another gastrointestinal (GI) illness outbreak aboard the National Geographic Sea Bird, marking the fourth outbreak reported on the ship since late May. The latest outbreak occurred during a voyage from July 15 to July 20, 2026, raising continued concerns about the spread of stomach illnesses on...